Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Identification of a serum biomarker signature associated with metastatic prostate cancer

Kuci Emruli, Venera LU ; Liljedahl, Leena LU ; Axelsson, Ulrika LU orcid ; Richter, Corinna LU ; Theorin, Lisa LU ; Bjartell, Anders LU ; Lilja, Hans LU orcid ; Donovan, Jenny ; Neal, David and Hamdy, Freddie C. , et al. (2021) In Proteomics - Clinical Applications 15(2-3).
Abstract

Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy... (More)

Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. Conclusions and clinical relevance: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
affinity proteomics, antibody microarrays, biomarkers, cancer, prostate cancer
in
Proteomics - Clinical Applications
volume
15
issue
2-3
article number
2000025
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85104226510
  • pmid:33580906
ISSN
1862-8346
DOI
10.1002/prca.202000025
language
English
LU publication?
yes
id
aac366b9-e056-4452-a7ad-e74238c8b24e
date added to LUP
2021-04-26 14:52:59
date last changed
2025-03-23 14:21:55
@article{aac366b9-e056-4452-a7ad-e74238c8b24e,
  abstract     = {{<p>Purpose: Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease. Experimental design: In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray. Results: A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified. Conclusions and clinical relevance: The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.</p>}},
  author       = {{Kuci Emruli, Venera and Liljedahl, Leena and Axelsson, Ulrika and Richter, Corinna and Theorin, Lisa and Bjartell, Anders and Lilja, Hans and Donovan, Jenny and Neal, David and Hamdy, Freddie C. and Borrebaeck, Carl A.K.}},
  issn         = {{1862-8346}},
  keywords     = {{affinity proteomics; antibody microarrays; biomarkers; cancer; prostate cancer}},
  language     = {{eng}},
  month        = {{05}},
  number       = {{2-3}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Proteomics - Clinical Applications}},
  title        = {{Identification of a serum biomarker signature associated with metastatic prostate cancer}},
  url          = {{http://dx.doi.org/10.1002/prca.202000025}},
  doi          = {{10.1002/prca.202000025}},
  volume       = {{15}},
  year         = {{2021}},
}